Vasamed Acquires Impedance Cardiography Technology

In a transaction designed to expand its line of diagnostic products, Vasamed (Minneapolis, MN, USA) has announced the acquisition of proprietary impedance cardiography technology for noninvasive cardiac output (NICO) monitoring.

"In keeping with our mission to build a line of office-based diagnostic products that incorporate our wholly-owned intellectual property in blood flow and tissue perfusion, we are pleased to add NICO based on impedance cardiography (ICG),” said Paulita LaPlante, president and CEO of Vasamed. "This product is one of very few FDA-cleared systems that measure ICG. The most notable competitor is Cardiodynamics.”

Vasamed acquired the ICG technology from a private company that expended time and resources developing proprietary algorithms and securing clearance by the U.S. Food and Drug Administration (FDA). Vasamed will refine the user-interface software and modify certain performance features and hardware before introducing a product to market. With this acquisition, the company believes it controls the principal components of the hemodynamic health platform it set out to create following the introduction of tissue carbon dioxide monitoring in 2000.

Vasamed is a technology development company specializing in low-cost, noninvasive vascular diagnostic systems for hemodynamic monitoring. Products developed by the company include the CapnoProbe sensor system for the measurement of sublingual CO2.




Related Links:
Vasamed